Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hanmi-pharm-co-ltd" target="_blank" data-smartkarma-citation="entities:12476:1" rel="noopener">Hanmi Pharm (128940 KS)</a> reported 2Q26 result, with operating profit surging 117% YoY to KRW131B, driven by upfront revenue received from global outlicensing deal with Lilly for sonefeglutide.</li>
<li>Reacting to 2Q26 result, Hanmi Pharm shares nosedived. Muted core business, weakness in China subsidiary, and expected increase in operating expenses raise concern over the near-term growth prospect.</li>
<li>The company has reached to an inflection point, where it is ready to reap the benefit of innovation prowess. Its GLP-1-based drug candidate Efpeglenatide aims for commercialization within the year.</li>
</ul>



Hanmi Pharm (128940 KS) reported 2Q26 result, with operating profit surging 117% YoY to KRW131B, driven by upfront revenue received from global outlicensing deal with Lilly for sonefeglutide.
Reacting to 2Q26 result, Hanmi Pharm shares nosedived. Muted core business, weakness in China subsidiary, and expected increase in operating expenses raise concern over the near-term growth prospect.
The company has reached to an inflection point, where it is ready to reap the benefit of innovation prowess. Its GLP-1-based drug candidate Efpeglenatide aims for commercialization within the year.


Hanmi Pharm (128940 KS): Why Shares Plunge Despite Record High 2Q Operating Profit; What Lies Ahead

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares MSCI ACWI ETF / Technical Analysis

<ul>
<li>There continues to be little traction above $93 on MSCI ACWI (ACWI-US), which remains the top-end of our anticipated 2023 trading range. Important downside targets are $86, $84, and $75-77.</li>
<li>Additionally, the EURO STOXX 50 remains below 2-year resistance at 4400-4415.</li>
<li>We remain overweight Europe, Japan, and India, and we prefer to only add exposure on a pullback -- especially in Japan where indexes are bullish yet extended.</li>
</ul>


There continues to be little traction above $93 on MSCI ACWI (ACWI-US), which remains the top-end of our anticipated 2023 trading range. Important downside targets are $86, $84, and $75-77.
Additionally, the EURO STOXX 50 remains below 2-year resistance at 4400-4415.
We remain overweight Europe, Japan, and India, and we prefer to only add exposure on a pullback -- especially in Japan where indexes are bullish yet extended.


No Traction Above $93 on ACWI-US or 4400-4415 on EURO STOXX 50. Buys in Defensives/Japan/EM

SK Biopharmaceuticals   / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals (326030 KS)</a> announced strong 1Q26 result, with revenue increasing 58% YoY and 17% QoQ to KRW228B, with Xcopri U.S. revenue increasing 48% YoY and 16% QoQ to KRW198B.</li>
<li>This quarter is significant in that operating profit approached approximately KRW90B, reaching an all-time high despite increased research and development and marketing expenses compared to the previous year. </li>
<li>For full-year 2026, SKBP guided for Xcopri U.S. revenue of $550–580M, up 24–31% YoY. Considering 1Q26 momentum, the company is well-positioned to meet the guidance.</li>
</ul>



SK Biopharmaceuticals (326030 KS) announced strong 1Q26 result, with revenue increasing 58% YoY and 17% QoQ to KRW228B, with Xcopri U.S. revenue increasing 48% YoY and 16% QoQ to KRW198B.
This quarter is significant in that operating profit approached approximately KRW90B, reaching an all-time high despite increased research and development and marketing expenses compared to the previous year. 
For full-year 2026, SKBP guided for Xcopri U.S. revenue of $550–580M, up 24–31% YoY. Considering 1Q26 momentum, the company is well-positioned to meet the guidance.


SK Biopharmaceuticals (326030 KS): Record High Operating Profit in 1Q; Xcopri Guidance Maintained

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Thematic (Sector/Industry)

<p><strong>Bonifas and Barrett</strong> may not be household names to most people. They were two US Army officers stationed in South Korea who were killed by North Korean soldiers in 1976. Bonifas and Barrett were cutting down part of a tree in the JSA (Joint Security Area) in the Korean Demilitarized Zone. They were killed over a stupid tree because North Koreans believed this tree was planted by Kim Il-Sung, the founder of North Korea. From then on, this was known as the <em>Axe Murder Incident</em>. At the time, a 24…</p>

Bonifas and Barrett may not be household names to most people. They were two US Army officers stationed in South Korea who were killed by North Korean soldiers in 1976. Bonifas and Barrett were cutting down part of a tree in the JSA (Joint Security Area) in the Korean Demilitarized Zone. They were killed over a stupid tree because North Koreans believed this tree was planted by Kim Il-Sung, the founder of North Korea. From then on, this was known as the Axe Murder Incident. At the time, a 24…

How Will South Korea Change With Moon as Its Next President? (Top 10 Issues)

<ul>
<li><div class="content-highlight">In this report, we have identified 26 stocks in the Korean stock market that have announced share buyback programs so far in 2017. These stocks that have been buying back their shares have been outperforming the market in recent weeks. Share buybacks continue to be an "alpha generating" catalyst in the Korean stock market. Time and again, companies that buyback stocks in Korea tend to outperform the market.</div></li>
<li><p>For example, these 26 stocks that have announced share repurchase programs in 2017 are up…</p></li>
</ul>


In this report, we have identified 26 stocks in the Korean stock market that have announced share buyback programs so far in 2017. These stocks that have been buying back their shares have been outperforming the market in recent weeks. Share buybacks continue to be an "alpha generating" catalyst in the Korean stock market. Time and again, companies that buyback stocks in Korea tend to outperform the market.
For example, these 26 stocks that have announced share repurchase programs in 2017 are up…


Alpha Generation from Share Buybacks in Korea (2017 YTD)

South Korea

Yuhan Corporation manufactures and markets various pharmaceutical products on its own and through joint ventures with other global pharmaceutical companies. The Company also produces personal care products, dietary supplements, and veterinary medicines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yuhan Corp (000100 KS)

Hanmi Pharm (128940 KS): Why Shares Plunge Despite Record High 2Q Operating Profit; What Lies Ahead

Hanmi Pharm outlicenses HM1732, next-generation muscle mass preserving obesity drug candidate with first-in-class potential, to Genentech for a...

Tina Banerjee

No Traction Above $93 on ACWI-US or 4400-4415 on EURO STOXX 50. Buys in Defensives/Japan/EM

No Traction Above $93 on MSCI $ACWI or 4400-4415 on EURO #STOXX 50. Continues to reinforce our view from early-January that $93 on ACWI caps upside...

Vermilion Research

SK Biopharmaceuticals (326030 KS): Record High Operating Profit in 1Q; Xcopri Guidance Maintained

SK Biopharmaceuticals reported strong 1Q26 results with revenue up 58% YoY, operating profit at all-time high, and guided for Xcopri U.S. revenue...

Tina Banerjee

How Will South Korea Change With Moon as Its Next President? (Top 10 Issues)

Bonifas and Barrett may not be household names to most people. They were two US Army officers stationed in South Korea who were killed by North...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hanmi Pharm (128940 KS): Why Shares Plunge Despite Record High 2Q Operating Profit; What Lies Ahead

Hanmi Pharm outlicenses HM1732, next-generation muscle mass preserving obesity drug candidate with first-in-class potential, to Genentech for a...

Tina Banerjee

No Traction Above $93 on ACWI-US or 4400-4415 on EURO STOXX 50. Buys in Defensives/Japan/EM

No Traction Above $93 on MSCI $ACWI or 4400-4415 on EURO #STOXX 50. Continues to reinforce our view from early-January that $93 on ACWI caps upside...

Vermilion Research

SK Biopharmaceuticals (326030 KS): Record High Operating Profit in 1Q; Xcopri Guidance Maintained

​SK Biopharmaceuticals reported strong 1Q26 results with revenue up 58% YoY, operating profit at all-time high, and guided for Xcopri U.S. revenue...

Tina Banerjee

How Will South Korea Change With Moon as Its Next President? (Top 10 Issues)

Bonifas and Barrett may not be household names to most people. They were two US Army officers stationed in South Korea who were killed by North...

Douglas Kim

Alpha Generation from Share Buybacks in Korea (2017 YTD)

In this report, we have identified 26 stocks in the Korean stock market that have announced share buyback programs so far in 2017. These stocks...

Douglas Kim

SK Biopharmaceuticals reported strong 1Q26 results with revenue up 58% YoY, operating profit at all-time high, and guided for Xcopri U.S. revenue...